Dedicated to improving care
Clinical Research
Elevating Urology Through Clinical Research
Conducting clinical research keeps us at the forefront of urology treatment and gives our patients access to promising treatments and expert knowledge. This research enables us to offer our patients in Philadelphia and surrounding counties the latest advancements in treatments.
Each clinical research trial follows strict guidelines to protect participants. Ask your doctor if there’s a trial that is right for you. Or call our Clinical Research Department at 610-667-0458.
Sponsors and CROs: Learn more about partnering with MidLantic Urology for your next urology trial.
Clinical Trials at MidLantic Urology
Clinical research trials play an essential role in bringing new treatments to our patients. Those who participate in trials enjoy the reassurance and security they get from being closely monitored, and the satisfaction that they are playing an important role in advancing medicine.
These clinical trials are currently available at MidLantic Urology.
Bladder Cancer
ABLE 22
NCT06545955
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
Learn MoreABLE 32
NCT06510374
A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
Learn MoreAstellas 7465-CL-0209
NCT07475806
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
Learn MoreCore-008
NCT06567743
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Learn MoreCRETO-EAP
NCT06443944
An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG
Learn MoreImmunity Bio- ResQ133A
NCT06800963
ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG
Learn MoreJanssen Moonrise-1
NCT06319820
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Learn MoreJnJ-NovaStar
NCT06500936
Evaluation of an mHealth Intervention to Promote Participation in Breast Cancer Screening in Argentina
Learn MoreTyra 302
NCT06995677
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)
Learn MoreProstate Cancer
comPas-PCR3001
NCT04898634
A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
Learn MoreDendreon Boost
NCT06134232
An Open-Label, Multicenter Study of Subjects With Metastatic Castrate-Resistant Prostate Cancer Treated With PROVENGE® and Boosted With A Single Infusion of Sipuleucel-T to Measure Immune Response
Learn MoreJnJ: PASenger PCR 3003
NCT07225946
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (KLK2-PASenger)
Learn MoreMK-004
NCT06136650
A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA)
Learn MoreMyriad-Polaris
NCT03872388
Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy
Learn MoreNovartis Act First
NCT06855277
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC (AcTFirst)
Learn MoreNovartis JSB462
NCT06991556
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Learn MorePfizer-Mevpro 3
NCT07028853
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Learn MoreTelix 301-biPASS
NCT07052214
PSMA PET Combined With MRI for the Detection of PCa (BiPASS)
Learn MoreTelix TLX591-203
NCT06520345
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
Learn MoreFor more information or to enroll in one of these trials, call MidLantic’s Clinical Research Department at 610-667-0458.
A Trusted Team
Clinical trials help scientists better understand disease and develop new medications, treatments, and devices. Our clinical research team is comprised of top physicians and specialists experienced in clinical research. We provide our patients with the opportunity to participate in clinical trials and gain access to the latest therapy and technology available to treat their urologic condition.
Led by Dr. Laurence Belkoff, D.O., F.A.C.O.S and Clinical Research Director Cheryl Zinar, RN, BSN, together oversee a dedicated research team of RNs, Research Assistants and Regulatory Specialists. Backed by a research committee of eight board certified physicians, we continually strive to advance urology health.
